Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples